Abiraterone (Abiraterone Ascend)
Abiraterone
Ascend Laboratories (Pty) Ltd
Registration
- Applicant
- Ascend Laboratories (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Abiraterone 250 MG ascend EACH TABLET CONTAINS ABIRATERONE 250,0 mg | 250 mg | 54082554/21.12/0825 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Abiraterone
Consolidated Schedules 06 July 2026, line 5131
S4: Niraparib
Consolidated Schedules 06 July 2026, line 7281
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
(3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
Drag to rotate. Structure from PubChem CID 132971.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.